FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

					Or -	Section	n 30(n) c	or the	investment	Con	ipany Act	01 1940								
Name and Address of Reporting Person* Chiniara Ellen						2. Issuer Name and Ticker or Trading Symbol Compass Therapeutics, Inc. [CMPX]									Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Chimara Effett						1			,			,		X	Directo	r		10% Ov	vner	
(Last) (First) (Middle) C/O COMPASS THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/08/2023										Officer (give title below)				specify	
80 GUEST STREET, SUITE 601																				
					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X Form filed by One Reporting Person						
BOSTO	BOSTON MA		02135											Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						ar) E	2A. Deemed Execution Date, if any (Month/Day/Yea		Transaction Disposed Code (Instr. 5)			ties Acquir I Of (D) (Ins				es Form ally (D) of Following (I) (II		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o	Price		Transact (Instr. 3 a	ction(s)			(IIISU. 4)	
		•	Table II - D						uired, Di					y O	wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	ransaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Do	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode	٧	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares							
Stock Option	¢2.02	02/08/2022					40,000		(1)	0.	2/07/2022	Common	40.000		6 0	40.000	0	D		

02/07/2033

Explanation of Responses:

(Right to Buy)

\$3.93

1. The options vest over 48 substantially equal monthly installments starting March 8, 2023.

02/08/2023

/s/ Neil Lerner, attorney-in-fact 02/09/2023

\$<mark>0</mark>

40,000

D

** Signature of Reporting Person Date

40,000

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

40,000

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).